Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
CATC Lunenburg, CH van der Wouden… - European Journal of …, 2020 - nature.com
Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and …
Fluoropyrimidines (FPs), mainly 5-fluorouracil (5-FU) and its oral prodrug capecitabine
(Cap), remain the backbone of the treatment of many different solid tumors. Despite their …
(Cap), remain the backbone of the treatment of many different solid tumors. Despite their …
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD …
P García-Alfonso, M Saiz-Rodríguez… - Clinical and …, 2022 - Springer
Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the
treatment of cancer, especially gastrointestinal tumors and breast cancer, but their …
treatment of cancer, especially gastrointestinal tumors and breast cancer, but their …
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide
F Innocenti, SC Mills, H Sanoff, J Ciccolini… - JCO Oncology …, 2020 - ascopubs.org
Fluoropyrimidines (fluorouracil, capecitabine, and other analogs) are highly used anticancer
drugs worldwide. However, patients with cancer treated with these drugs might experience …
drugs worldwide. However, patients with cancer treated with these drugs might experience …
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update
U Amstutz, LM Henricks, SM Offer… - Clinical …, 2018 - Wiley Online Library
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
Clinical relevance of DPYD variants c. 1679T> G, c. 1236G> A/HapB3, and c. 1601G> A as predictors of severe fluoropyrimidine-associated toxicity: a systematic …
D Meulendijks, LM Henricks, GS Sonke… - The Lancet …, 2015 - thelancet.com
Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
MJ Deenen, D Meulendijks, A Cats… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
U Amstutz, S Farese, S Aebi, CR Largiader - Pharmacogenomics, 2009 - Taylor & Francis
Aims: The importance of polymorphisms in the dihydropyrimidine dehydrogenase gene
(DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is …
(DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU)-based chemotherapy is …
[HTML][HTML] Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed
anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine …
anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine …